ADPKD, or autosomal dominant polycystic kidney disease, can cause severe pain, headaches, and more problems. What can you do to feel better and stay active? Find exercise and diet tips, pain ...

A multicenter study from the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease has furthered understanding of the relationship between rates of kidney enlargement and decline ...

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

The role of polycystin 1 and 2 in the regulation of cell adhesion. The role of microRNAs in the pathogenesis of ADPKD. Trafficking of the polycystin proteins.

Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60. Approximately 160,000 ...

Autosomal dominant polycystic kidney disease (ADPKD) is the most common, potentially lethal genetic disorder characterized by the progressive enlargement of numerous fluid-filled cysts and the ...

Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant polycystic kidney disease (ADPKD).

Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from ...